Dr. Wykoff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
23501 Cinco Ranch Blvd
Ste G205
Katy, TX 77494Phone+1 713-524-3434Fax+1 713-524-3220- Is this information wrong?
Summary
- Board Certified by the American Board of Ophthalmology. Partner at Retina Consultants of Houston & Clinical Assistant professor at Weill Cornell Medical College, Houston Methodist Hospital. Research interests: angiogenesis & exudative retinal diseases as well as vitreoretinal surgery topics including trauma, retinal detachments, diabetic retinopthay, & macular holes. Principle investigator on numerous clinical trials including novel approaches to treating AMD, RVO and diabetic retinopathy. Member of the Macula Society, ASRS, AAO, and ARVO.
Education & Training
B Palmer Eye Institute - A B Leach EyeChief Residency, Chief Resident & Co-Director of Ocular Trauma, 2010 - 2011
University of Miami Hospital and ClinicsFellowship, Surgical Retina and Vitreous, 2009 - 2011
University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2006 - 2009
Brigham and Women's HospitalInternship, Internal Medicine, 2005 - 2006
Harvard Medical SchoolClass of 2005
Certifications & Licensure
TX State Medical License 2011 - 2024
FL State Medical License 2009 - 2015- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Start of enrollment: 2012 Oct 01
- Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab Start of enrollment: 2012 Dec 01
- A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Correction: Retinal non-perfusion: recognizing and defining what is important.Jessica A Cao, Varun Chaudhary, Hasenin Al-Khersan, Charles C Wykoff> ;Eye. 2024 Mar 28
- Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.Helene Karcher, Eser Adiguzel, Andrew Mayhook, Andrew LaPrise, Ver L Bilano, Franklin Igwe, Marco A Zarbin, Mathew W MacCumber, Michael S Ip, Charles C Wykoff> ;Ophthalmology and Therapy. 2024 Mar 23
- Suprachoroidal Space Injection Technique: Expert Panel Guidance.Cunningham, E., Ciulla, T., Wykoff, C., Avery, R., Barakat, M., Boyer, D., Brown, D., Brucker, A., Heier, J., Holekamp, N., Kaiser, P., Khanani, A., Kim, J., Demirci, ...> ;Retina. 2024 Mar 5
- Join now to see all
Journal Articles
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyCharles C Wykoff, Srinivas R Sadda, JAMA Ophthalmology
- Comparison of Early Treatment Diabetic Retinopathy Study Standard 7-Field Imaging with Ultrawide-Field Imaging for Determining Severity of Diabetic RetinopathyLee M Jampol, Lloyd Paul Aiello, Jennifer K Sun, Szilard Kiss, Charles C Wykoff, Neil M Bressler, JAMA
Authored Content
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
- Association of Intravitreal Aflibercept with Optical Coherence Tomography Angiography Vessel Density in Patients with Proliferative Diabetic RetinopathyJune 2020
Press Mentions
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual FunctionMay 24th, 2023- REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform ProcessFebruary 13th, 2023
- Geographic Atrophy Drug Development Meets Its FutureDecember 8th, 2022
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Memorial Hermann Southeast HospitalHouston, Texas
Houston Methodist HospitalHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
